Tumor immunotherapy is a therapeutic strategy involving reinitiating and maintaining tumor immune cycle and restoring the body's normal anti-tumor immune responses so as to inhibit tumor growth and eliminate tumor cells. Examples of such products include monoclonal antibody immune checkpoint blockades, therapeutic antibodies, cancer vaccines, cell therapies, and small molecule inhibitors. In the last few years, numerous achievements in the field of tumor immunotherapy. Many immunotherapeutic products have exhibited potent anti-tumour activity in the treatment of several solid tumors such as melanoma, non-small cell lung cancer, kidney cancer and prostate cancer and have been granted approvals for clinical use by FDA. Tumor immunotherapy was awarded as the most important scientific breakthrough by Science in 2013 for its excellent efficacy and innovation.

Respiratory syncytial virus (RSV) is the most common pathogen causing viral pneumonia in children. RSV usually occurs in neonates and infants less than 6 months old, but also occurs in immunocompromised and elderly people. RSV causes cells to produce devastating reactive oxygen species (ros) molecules that drive cells to release signals to and overreact to the immune system, producing inflammatory responses similar to asthma attacks.